110.83
前日終値:
$109.08
開ける:
$110.1
24時間の取引高:
9.91M
Relative Volume:
1.19
時価総額:
$192.72B
収益:
$44.33B
当期純損益:
$6.48B
株価収益率:
29.93
EPS:
3.7033
ネットキャッシュフロー:
$6.92B
1週間 パフォーマンス:
+1.40%
1か月 パフォーマンス:
-13.26%
6か月 パフォーマンス:
-15.35%
1年 パフォーマンス:
-13.56%
Abbott Laboratories Stock (ABT) Company Profile
名前
Abbott Laboratories
セクター
電話
(224) 667-6100
住所
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ABT
Abbott Laboratories
|
110.83 | 189.68B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
358.29 | 138.60B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
102.90 | 131.98B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
76.27 | 115.14B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.71 | 45.32B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-10 | 開始されました | The Benchmark Company | Buy |
| 2025-07-18 | アップグレード | Jefferies | Hold → Buy |
| 2025-06-16 | 開始されました | Leerink Partners | Market Perform |
| 2024-10-08 | 開始されました | Oppenheimer | Outperform |
| 2024-09-19 | 開始されました | Piper Sandler | Overweight |
| 2024-07-30 | ダウングレード | Edward Jones | Buy → Hold |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2023-07-21 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 繰り返されました | Barclays | Overweight |
| 2023-04-20 | 繰り返されました | Bernstein | Outperform |
| 2023-04-20 | 繰り返されました | JP Morgan | Overweight |
| 2023-04-20 | 繰り返されました | Raymond James | Outperform |
| 2023-04-20 | 繰り返されました | UBS | Buy |
| 2023-04-20 | 繰り返されました | Wolfe Research | Underperform |
| 2023-03-29 | 開始されました | UBS | Buy |
| 2022-10-26 | 開始されました | Mizuho | Neutral |
| 2022-10-18 | 開始されました | Barclays | Overweight |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-07-06 | 開始されました | Wolfe Research | Underperform |
| 2022-03-02 | 再開されました | BofA Securities | Buy |
| 2022-01-27 | 繰り返されました | Credit Suisse | Outperform |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-01-27 | 繰り返されました | Raymond James | Outperform |
| 2022-01-27 | 繰り返されました | UBS | Buy |
| 2021-12-10 | 開始されました | RBC Capital Mkts | Outperform |
| 2021-10-27 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 開始されました | Redburn | Neutral |
| 2021-05-25 | 開始されました | Barclays | Overweight |
| 2021-04-15 | 開始されました | Atlantic Equities | Neutral |
| 2021-01-28 | アップグレード | BTIG Research | Neutral → Buy |
| 2020-09-11 | 開始されました | Wolfe Research | Outperform |
| 2020-06-01 | ダウングレード | Goldman | Neutral → Sell |
| 2020-03-05 | 開始されました | Citigroup | Buy |
| 2020-02-13 | 開始されました | Goldman | Neutral |
| 2020-02-06 | 再開されました | BTIG Research | Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-06-13 | 繰り返されました | BofA/Merrill | Buy |
| 2019-02-07 | 繰り返されました | BofA/Merrill | Buy |
| 2019-01-02 | ダウングレード | Citigroup | Neutral → Sell |
| 2018-11-30 | アップグレード | Goldman | Neutral → Buy |
| 2018-10-16 | 開始されました | Barclays | Overweight |
| 2018-06-27 | 開始されました | Bernstein | Outperform |
| 2018-01-30 | 繰り返されました | Citigroup | Neutral |
| 2018-01-25 | 繰り返されました | Stifel | Buy |
| 2018-01-25 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 開始されました | Evercore ISI | Outperform |
| 2018-01-02 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-01-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-10-19 | 繰り返されました | Stifel | Buy |
すべてを表示
Abbott Laboratories (ABT) 最新ニュース
Abbott Laboratories (ABT): Short-Term Headwinds, Strategic Pipeline Strength, and UBS Buy Rating - Finviz
Abbott stock price: what to watch Monday after FDA Libre recall update, insider buy - TechStock²
Analysts’ Top Healthcare Picks: Mettler-Toledo (MTD), Abbott Laboratories (ABT) - The Globe and Mail
Top Abbott Insider Quietly Makes a Bold Million-Dollar Move - TipRanks
Abbott Labs CEO makes $2M bet as stock sinks - thestreet.com
Abbott Laboratories Announces Measurable Results From LATAM Diagnostic Market Development and Training Initiative Led by Claudia Marcela Riaño Caro - PRWeb
Exact Sciences (EXAS) Advances as HSR Period Expires for Abbott Deal - GuruFocus
Abbott studies support pulsed field ablation, dual ablation catheters - MassDevice
Abbott Stock: 2026 Recovery Outlook After a 17% Decline - TIKR.com
Abbott (ABT) Showcases Promising AFib Therapy Advances at Boston Symposium - GuruFocus
Abbott reports positive results from study on its atrial fibrillation therapies - AlphaStreet News -
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance Singapore
Abbott’s atrial fibrillation treatments show strong results in new studies By Investing.com - Investing.com India
Abbott Labs director Starks buys shares worth $1.08 million By Investing.com - Investing.com India
Catheter trials show Abbott devices cut AFib episodes for most patients - stocktitan.net
UK’s NICE recommends Abbott’s Cardiomems heart failure system - BioWorld MedTech
Abbott on track with dual sensor, FDA warns on FreeStyle Libre - Modern Healthcare News
BTIG Reaffirms Their Buy Rating on Abbott Laboratories (ABT) - The Globe and Mail
US FDA says injuries from Abbott’s recalled glucose sensors reach 860 - WHTC
Abbott Laboratories: How a 136-Year-Old Medtech Giant Is Re?Engineering the Future of Diagnostics an - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
US FDA says injuries from Abbott's recalled glucose sensors reach 860 - marketscreener.com
Abbott recalls glucose sensors after seven deaths linked to faulty readings - marketscreener.com
Abbott Laboratories (ABT) Faces FDA's Most Serious Recall Over G - GuruFocus
Abbott glucose monitor recall classified as most serious (ABT) - Seeking Alpha
Do Wall Street Analysts Like Abbott Laboratories Stock? - Barchart.com
FDA demands better response from Abbott over Libre inspection violations - Fierce Biotech
Hantz Financial Services Inc. Sells 29,746 Shares of Abbott Laboratories $ABT - MarketBeat
Envestnet Asset Management Inc. Sells 169,808 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock Now 18% Cheaper, Time To Buy - Trefis
Gains Report: Can Abbott Laboratories sustain earnings growthDay Trade & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Abbott receives FDA warning letter related to FreeStyle Libre CGMs - MassDevice
2 Healthcare Dividend Stocks That are Just What the Doctor Ordered - The Motley Fool
Abbott Faces FDA Scrutiny On FreeStyle Libre And Broader Quality Story - Yahoo Finance
Abbott (ABT) stock slips on FDA warning letter over FreeStyle Libre testing; dates to watch - TechStock²
Abbott CEO Share Purchase Highlights $21b Exact Sciences Deal And Valuation - simplywall.st
Abbott receives FDA warning letter over Freestyle Libre CGMs - MedTech Dive
Abbott (ABT) Faces Profit Headwinds as Pediatric Nutrition Remains Under Pressure - Finviz
OTC/DTC Infectious Disease Diagnostics Research Report 2026: Market Strategies, Trends, and Forecasts 2025-2029 - GlobeNewswire Inc.
Sollinda Capital Management LLC Sells 15,866 Shares of Abbott Laboratories $ABT - MarketBeat
Jones Financial Companies Lllp Buys 61,627 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stake Lessened by Thrivent Financial for Lutherans - MarketBeat
Abbott Laboratories (ABT): A Bull Case Theory - Insider Monkey
Abbott (ABT) Sees Increased Bearish Options Activity - GuruFocus
Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date - TechStock²
Abbott’s Exact Sciences Deal Recasts Diagnostics While Nutrition Faces Reset - Yahoo Finance
Abbott stock price today: ABT slips after Barclays cuts target as Wall Street resets expectations - TechStock²
The Best Dividend King to Buy With $150 - AOL.com
ABT: Barclays Adjusts Abbott Laboratories Price Target to $142 | - GuruFocus
Abbott Laboratories (NYSE:ABT) Price Target Cut to $142.00 by Analysts at Barclays - MarketBeat
Abbott: Long-Term Investment Opportunity For Dividend Growth Investors - Seeking Alpha
Abbott Laboratories (ABT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):